Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

23 trials with published results (14%)

Research Maturity

92 completed trials (55% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.0%

10 terminated out of 168 trials

Success Rate

90.2%

+3.7% vs benchmark

Late-Stage Pipeline

14%

23 trials in Phase 3/4

Results Transparency

25%

23 of 92 completed with results

Key Signals

23 with results90% success

Data Visualizations

Phase Distribution

116Total
Not Applicable (36)
Early P 1 (4)
P 1 (29)
P 2 (24)
P 3 (19)
P 4 (4)

Trial Status

Completed92
Recruiting21
Unknown20
Terminated10
Withdrawn9
Active Not Recruiting7

Trial Success Rate

90.2%

Benchmark: 86.5%

Based on 92 completed trials

Clinical Trials (168)

Showing 20 of 20 trials
NCT03030248Phase 2Completed

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT04094844Not ApplicableCompletedPrimary

Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation

NCT04450927Enrolling By Invitation

Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors

NCT04208529Phase 3Enrolling By Invitation

A Long-term Follow-up Study in Participants Who Received CTX001

NCT05969821Not Yet Recruiting

Clonal Hematopoiesis of Immunological Significance

NCT05477563Phase 3Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

NCT07387354Phase 1Not Yet Recruiting

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

NCT05356195Phase 3Active Not Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

NCT06797375Phase 1CompletedPrimary

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants

NCT05895994Early Phase 1Completed

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

NCT01287000Active Not Recruiting

Gulf Long-Term Follow-Up Study

NCT03842696Phase 1Active Not RecruitingPrimary

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT05443321Not ApplicableEnrolling By Invitation

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

NCT07364409Not ApplicableActive Not Recruiting

Autologous Transplantation of Human Cryopreserved Testis Tissue

NCT05660265Phase 1TerminatedPrimary

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT04640987Phase 1RecruitingPrimary

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

NCT00186147Enrolling By Invitation

Bone Marrow Grafting for Leukemia and Lymphoma

NCT03655678Phase 2Completed

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT07257640Phase 1RecruitingPrimary

IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

NCT04167683Active Not RecruitingPrimary

Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant

Scroll to load more

Research Network

Activity Timeline